Drug intelligence / Profile preview

Product B

Development stage: Preclinical
Lead developer: IdentiRx
Modality: Small Molecules
Administration: Otic

Overview

Product B is an investigational otic drug candidate developed by IdentiRx, utilizing the company's proprietary unit-dose delivery technology. This technology is designed to provide sterile, preservative-free, and precisely measured doses of medication for the treatment of various ear conditions. By using single-use packaging, IdentiRx aims to improve patient safety by reducing the risk of microbial contamination and ensuring accurate dosing compared to traditional multi-dose otic containers. As of the current pipeline status, the specific active pharmaceutical ingredient and the exact clinical indications for Product B have not been publicly disclosed.

Other names: Product B-IdentiRx-Otic Unit Dose-oticIdentiRx Otic Unit Dose

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on Product B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Product B.

Explore the full profile